Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester Disease
Abstract
Background Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis. The BRAF inhibitor vemurafenib is approved by the U.S. Food and Drug Administration (FDA) for patients with ECD harboring a BRAF V600E mutation. Successful treatment has also been reported with MEK-targeted therapies, likely because of the fact that BRAF mutant–negative patients harbor MEK pathway alterations. In our Rare Tumor Clinic, we noted that these...
Paper Details
Title
Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester Disease
Published Date
Nov 19, 2019
Journal
Volume
25
Issue
2
Pages
e386 - e390
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History